Over 22 Million Children Missed First Vaccine Dose as Global Immunization Coverage Lags
WHO and CDC released joint epidemiological surveillance report on November 14, 2026, confirming global measles cases climbed 20% year-over-year in 2023, reaching an estimated 10.3 million infections; inadequate national routine immunization coverage triggered severe disease outbreaks across 57 countries. According to data in CDC's Morbidity and Mortality Weekly Report (MMWR), the surge reflects widespread childhood immunization disruptions; estimated global fatalities fell by 8% to 107,500 deaths, principally infants and children under five, while countries with large or disruptive outbreaks rose from 36 in 2022 to 57 in 2023, affecting nearly all six WHO geographic administrative regions.
Routine immunization coverage data showed 83% of eligible children received their first dose of the measles-containing vaccine (MCV1) in 2023, while only 74% received the recommended second dose (MCV2); more than 22 million infants missed their initial scheduled measles vaccine dose worldwide. WHO Director-General Dr. Tedros Adhanom Ghebreyesus stated: "Measles vaccine has saved more lives than any other vaccine in the past 50 years, and to save even more lives we must invest in immunization for every person no matter where they live."
Epidemiological specialists emphasized measles virus possesses a basic reproduction number (R0) between 12 and 18; European Union member states recorded a more than thirty-fold increase in documented measles cases during 2023. Two recommended doses of validated measles vaccines deliver over 97% permanent efficacy against symptomatic disease. WHO, UNICEF, and Gavi deployed coordinated immunization catch-up frameworks targeting 24 lower-income countries, with dedicated humanitarian immunization funding aiming to reach more than 100 million vulnerable children with supplemental vaccination campaigns throughout the upcoming operational period. United States CDC global health teams reaffirmed continued technical support for regional laboratory surveillance networks and cold-chain vaccine storage installations across West Africa and Southeast Asia.
